CellCept

(Mycophenolate Mofetil)

ApprovedSmall molecule

Mycophenolate mofetil is used to prevent the body's immune system from rejecting transplanted organs like kidneys, hearts, or livers. It's also used to treat certain autoimmune diseases where the immune system attacks the body's own tissues.[2] CellCept is currently approved and in use across 86 indications[4].[1]

CellCept is one of 1025 small molecule programs targeting Kidney Transplant. It is currently in Approved.

Indications

622

Total Trials

Active Trials

1,024

Competitors

176

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Kidney TransplantTerminated

Iga NephropathyUnknown status

Aplastic AnemiaRecruiting

Bone Marrow TransplantationTerminated

Systemic SclerosisRecruiting

MalignanciesCompleted

Hematological MalignanciesCompleted

Total Body IrradiationCompleted

IGA GlomerulonephritisApproved

Cardiovascular DiseaseApproved

Kidney TransplantApproved

Terminated

Iga NephropathyApproved

Unknown status

Aplastic AnemiaPhase 2

Recruiting

Bone Marrow TransplantationPhase 2

Terminated

Systemic SclerosisPhase 2

Recruiting

MalignanciesPhase 2

Completed

Hematological MalignanciesPhase 2

Completed

Total Body IrradiationPhase 2

Completed

IGA GlomerulonephritisApproved

Approved

Cardiovascular DiseaseApproved

Approved

Showing 10 of 86 indications

Competition

Competitive Landscape

375 competitors in Lymphoma

#DrugCompanyPhaseTrials

CellCept

Roche

Approved

13 2

Zofran

Novartis

Preclinical

2 3

Norvir

AbbVie

Preclinical

1 4

Cabenuva

GSK

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Not yet recruiting

Uveitis

NCT06258915

Phase 1/2Active, not recruiting

Acute Myeloid Leukemia

NCT03247088

Q1 2028

Phase 1/2Recruiting

Total Body Irradiation

NCT04083183

Q4 2028

Phase 1Recruiting

Stem Cell Transplant

NCT02333162

Post-ApprovalRecruiting

Lupus Nephritis

NCT05207358

Phase 2Recruiting

Bone Marrow Failure

NCT04232085

Clinical

Trials by Indication[1]

Kidney Transplant18 trials

Mycophenolate Mofetil (MMF) Discontinuation From a Tacrolimus/MMF/Steroid Triple Regimen After Kidney Transplantation

Completed· Astellas logo

Astellas·Phase 3·NCT00693381·152 enrolled

Polycystic Liver Disease in Kidney Transplant

Terminated·MMayo Clinic·N/A·NCT00934791·2 enrolled

Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate Mofetil

Completed· Novartis logo

Novartis·Phase 4·NCT00400647·136 enrolled

Show 15 more trials

Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00790439

Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients

Unknown status·LLee's Pharmaceutical Limited·Phase 4·NCT06114953·152 enrolled

A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.

Completed· Astellas logo

Astellas·Phase 4·NCT01363752·853 enrolled

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

Completed·JJohns Hopkins University·Phase 3·NCT00275509·56 enrolled

Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients

Active, not recruiting· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 4·NCT05193565·206 enrolled

The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients

Completed·MMayo Clinic·Phase 4·NCT00275535·165 enrolled

Improved Induction and Maintenance Immunosuppression in Kidney Transplantation

Completed·UUniversity of Nebraska·Phase 4·NCT00556933·180 enrolled

An Observational Study on Renal Function in Kidney Transplant Participants on Immunosuppressive Therapy Containing Mycophenolate Mofetil

Completed· Roche logo

Roche··NCT01672957·128 enrolled

Validation of Population Pharmacokinetic Model Derived From Healthy Volunteer in Kidney Transplant Recipients

Unknown status·SSeoul National University Hospital··NCT02808065·40 enrolled

Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients

Completed·MMedical University of South Carolina·N/A·NCT02954198·40 enrolled

OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.

Completed· Roche logo

Roche·Phase 3·NCT02005562·252 enrolled

A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Kidney Transplantation

Completed· Astellas logo

Astellas·Phase 3·NCT00481819·240 enrolled

Iguratimod in Kidney Transplant Recipients

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT02839941·60 enrolled

Myfortic vs. Cellcept in Kidney Transplant Recipients

Completed·UUniversity of Miami·Phase 2/3·NCT00533624·150 enrolled

Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients

Completed·MMedical University of South Carolina·Phase 4·NCT02953873·25 enrolled

Stem Cell Transplant15 trials

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00230035

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Active, not recruiting·—·Phase 2·NCT00544115·260 enrolled

Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00317785·50 enrolled

Show 12 more trials

Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00255710·60 enrolled

Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers

Completed·UUniversity of California, Davis·Phase 2·NCT00619645·8 enrolled

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

Recruiting·UUniversity of Chicago·Phase 1·NCT02333162·30 enrolled

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

No longer available·BBarbara Ann Karmanos Cancer Institute··NCT00423826

Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT04776850

Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00423514·38 enrolled

Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders

Unknown status·IInstitut Paoli-Calmettes·Phase 2·NCT00740467·50 enrolled

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Completed·OOHSU Knight Cancer Institute·Phase 1/2·NCT00245037·147 enrolled

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00006251·21 enrolled

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT01300572·16 enrolled

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00053196·82 enrolled

Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer

Completed·NNorthside Hospital, Inc.·Phase 2·NCT00782379·20 enrolled

Hematologic Malignancies9 trials

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT01621477·34 enrolled

Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies

Completed·NNohla Therapeutics, Inc.·Phase 2·NCT01175785·15 enrolled

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Withdrawn·OOssium Health, Inc.·Phase 1·NCT05170828

Show 6 more trials

Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02120157·35 enrolled

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT01341301·25 enrolled

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT02566304·35 enrolled

Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies

Withdrawn·UUniversity of Medicine and Dentistry of New Jersey·Phase 2·NCT01652014

Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT

Terminated·SStanford University·Phase 1·NCT02728700·1 enrolled

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT01760655·62 enrolled

Lupus Nephritis8 trials

Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis

Recruiting·IInstitutul Clinic Fundeni·Phase 4·NCT05207358·30 enrolled

BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis

Terminated· Biogen logo

Biogen·Phase 2·NCT01930890·87 enrolled

Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis

Completed·—·Phase 3·NCT01042457·24 enrolled

Show 5 more trials

Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis

Completed·TThe University of Hong Kong·Phase 3·NCT02630628·130 enrolled

Multicenter Registry of Pediatric Lupus Nephritis in China

Unknown status·XXiqiang Dang··NCT03791827·1,200 enrolled

Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis

Terminated·—·Phase 4·NCT03920059·2 enrolled

The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment

Recruiting·NNanjing University School of Medicine·Phase 2·NCT07340463·50 enrolled

Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis

Completed·TTuen Mun Hospital·Phase 4·NCT00371319·150 enrolled

Kidney Cancer6 trials

Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00243009·1 enrolled

Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer

Withdrawn·FFox Chase Cancer Center·Phase 2·NCT00025519

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

Completed·UUniversity of Rochester·Phase 2·NCT00262886·35 enrolled

Show 3 more trials

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00005851·11 enrolled

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00078858·37 enrolled

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Completed·FFred Hutchinson Cancer Center·N/A·NCT00005799·55 enrolled

90 more indications

Acute Myeloid Leukemia5 trials

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT03247088·74 enrolled

Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00045435·17 enrolled

S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia

Terminated·SSWOG Cancer Research Network·Phase 2·NCT00053014·5 enrolled

Show 2 more trials

Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01252667·44 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02441803·11 enrolled

Acute Graft Versus Host Disease5 trials

PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis

Unknown status·NNanfang Hospital, Southern Medical University·Phase 4·NCT03689465·260 enrolled

Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00224874·180 enrolled

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00105001·210 enrolled

Show 2 more trials

Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

Completed·MMedical College of Wisconsin·Phase 3·NCT01002742·236 enrolled

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Terminated·UUniversity of Nebraska·Phase 2·NCT01044745·20 enrolled

Liver Transplant5 trials

Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids

Terminated· Roche logo

Roche·Phase 2·NCT02630563·9 enrolled

Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation

Completed·AAlbert Einstein Healthcare Network·Phase 4·NCT00206076·19 enrolled

The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1)

Unknown status· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 4·NCT01766518·120 enrolled

Show 2 more trials

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02188719·15 enrolled

Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects

Withdrawn·MMontefiore Medical Center·Phase 4·NCT03315052

Acute Lymphoblastic Leukemia4 trials

Busulfan and Cyclophosphamide Followed By ALLO BMT

Terminated·MMasonic Cancer Center, University of Minnesota·N/A·NCT01685411·5 enrolled

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT00589316·26 enrolled

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00988715·17 enrolled

Show 1 more trial

Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00027547

Lymphoma4 trials

Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT00041288·10 enrolled

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT01434472·20 enrolled

Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00387959·17 enrolled

Show 1 more trial

Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00119392·42 enrolled

Treatment4 trials

Treatment Strategies in IgG4-RD Patients With Re-elevation of Serum IgG4 Level During Maintenance Remission Period

Unknown status·PPeking Union Medical College Hospital·N/A·NCT05974683·108 enrolled

Alipogene Tiparvovec for the Treatment of LPLD Patients

Withdrawn·UUniQure Biopharma B.V.·Phase 2·NCT02904772

Mycophenolate Mofetil and Abacavir Treatment in HIV Patients With Failed Anti-HIV Treatment

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00021489

Show 1 more trial

Clinical Study of MMF in Treatment of IIM-ILD and Its Effect on Peripheral Blood Treg Cells

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 4·NCT05129410·20 enrolled

Renal Transplant Recipients4 trials

Calcineurin Free Immunosuppression in Renal Transplant Recipients

Completed·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT00812123·127 enrolled

Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients

Terminated·RRamesh Prasad·Phase 3·NCT01213394·2 enrolled

Pilot Study for HLA Identical Living Donor Renal Transplant Recipients

Completed·UUniversity of Cincinnati·Phase 4·NCT00352092·20 enrolled

Show 1 more trial

Selective CD28 Blockade in Renal Transplant Recipients

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04903054

Bone Marrow Transplantation4 trials

Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00003572·20 enrolled

Bone Marrow Transplantation in Treating Children With Sickle Cell Disease

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00004485·50 enrolled

Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00006042

Show 1 more trial

Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00008151

Systemic Lupus Erythematosus4 trials

Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE)

Completed·GGuy's and St Thomas' NHS Foundation Trust·Phase 4·NCT01101802·71 enrolled

Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus

Recruiting·CChinese SLE Treatment And Research Group·Phase 4·NCT05916781·220 enrolled

Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01946880·102 enrolled

Show 1 more trial

Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT02080195·1 enrolled

Efficacy and Safety4 trials

Efficacy and Safety of Mycophenolate Mofetil in subjectswithSjogren's Syndrome

Unknown status·KKaohsiung Medical University·Phase 2·NCT02691949·54 enrolled

Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT

Completed·—·Phase 4·NCT02677181·100 enrolled

A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . .

Terminated·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00451867·210 enrolled

Show 1 more trial

Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects

Completed·AAmsterdam Molecular Therapeutics·Phase 2/3·NCT00891306·5 enrolled

Nephrotic Syndrome4 trials

Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome

Recruiting·—·Phase 2·NCT05843968·46 enrolled

Compare Efficacy and Safety of Repeated Courses of Rituximab to That of Maintenance Mycophenolate Mofetil Following Single Course of Rituximab Among Children With Steroid Dependent Nephrotic Syndrome

Completed·UUnknown Sponsor·Phase 3·NCT03899103·100 enrolled

Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Nephrotic Syndrome

Completed·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 4·NCT04048161·270 enrolled

Show 1 more trial

Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment

Withdrawn·—·Phase 3·NCT04531865

Chronic Myelogenous Leukemia3 trials

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01904136·54 enrolled

Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00110058·40 enrolled

Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00119340·75 enrolled

Graft Versus Host Disease3 trials

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00089011·150 enrolled

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT02208037·279 enrolled

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

Completed·MMedical College of Wisconsin·Phase 3·NCT03959241·431 enrolled

Chronic Lymphocytic Leukemia2 trials

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01008462·16 enrolled

Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00425802·61 enrolled

Kidney2 trials

Shift to Everolimus (RAD) Kidney Sparing Study

Terminated·UUniversity of Bologna·Phase 4·NCT00420537·34 enrolled

Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients

Completed·UUniversity of Miami·Phase 2·NCT00533442·170 enrolled

Stem Cell Transplantation2 trials

Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT00044954

Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00006350

Renal Transplant2 trials

A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS)

Completed·IIrmandade Santa Casa de Misericórdia de Porto Alegre·Phase 4·NCT01822483·100 enrolled

Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients

Completed·NNational Taiwan University Hospital·Phase 4·NCT02077556·14 enrolled

Uveitis2 trials

Treatment FOr Corticosteroid Dependent UveitiS

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06258915·120 enrolled

First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial

Completed·UUniversity of California, San Francisco·Phase 3·NCT01232920·80 enrolled

Aplastic Anemia2 trials

Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00005935·130 enrolled

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Unknown status·UUniversity of California, San Francisco·N/A·NCT00295997·35 enrolled

Immunosuppression2 trials

Induction of Mixed Hemopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post Transplant in Immunosuppression w/CSA & Mycophenolate Mofetil

Unknown status·KKing Faisal Specialist Hospital & Research Center·Phase 1·NCT00531635·350 enrolled

Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk

Withdrawn·UUniversity of California, San Francisco·Phase 2·NCT04473924

Hematologic Disease2 trials

Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Unknown status·CCancer Research UK·Phase 2·NCT00959231·60 enrolled

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00376519·3 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation2 trials

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.

Withdrawn·NNationwide Children's Hospital·Phase 2·NCT00874315

A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors

Terminated·MMontefiore Medical Center·Phase 1·NCT02653196·1 enrolled

Pemphigus Vulgaris2 trials

A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)

Unknown status·TTongji Hospital·Phase 4·NCT05303272·60 enrolled

A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)

Completed· Roche logo

Roche·Phase 3·NCT02383589·135 enrolled

Safety and Efficacy2 trials

Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]

Unknown status·AAmsterdam Molecular Therapeutics·Phase 2/3·NCT01109498·14 enrolled

Study to Evaluate Safety and Efficacy of Early Calcineurin Inhibitor Withdrawal in Primary Renal Allografts

Completed·UUniversity of Cincinnati·Phase 4·NCT00374647·17 enrolled

Vasculitis2 trials

Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis

Completed·—·Phase 2/3·NCT00414128·140 enrolled

Anti-Cytokine Therapy for Vasculitis

Completed·UUniversity Hospital Birmingham NHS Foundation Trust·Phase 2·NCT00753103·37 enrolled

Hematopoietic Stem Cell Transplantation2 trials

A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 3·NCT04547049·176 enrolled

Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation

Terminated·—·Phase 2·NCT00548717·15 enrolled

Systemic Sclerosis2 trials

Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Completed·HHospital for Special Surgery, New York·Phase 2·NCT01670565·20 enrolled

Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis

Withdrawn·FFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium·Phase 2·NCT01047072

Histiocytosis1 trial

Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00334672·288 enrolled

Pancreatic Cancer1 trial

Study of CellCept for Advanced Pancreatic Cancer

Completed·—·Phase 1·NCT00997958·12 enrolled

Myeloproliferative Disorder1 trial

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

Completed·EEverett Meyer·Phase 2·NCT01392989·44 enrolled

Fasting Conditions1 trial

Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT00911274·53 enrolled

Natural Killer Cell1 trial

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00354172·16 enrolled

Allogeneic Stem Cell Transplantation1 trial

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06807606·35 enrolled

Hematological Malignancies1 trial

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01527045·47 enrolled

Trial1 trial

Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT

Terminated·SSt. Petersburg State Pavlov Medical University·Phase 2·NCT02627573·32 enrolled

Monoclonal1 trial

Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX

Completed· Astellas logo

Astellas·Phase 2·NCT00693524·94 enrolled

Juvenile Neuronal Ceroid Lipofuscinosis1 trial

Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis

Completed·UUniversity of Rochester·Phase 2·NCT01399047·19 enrolled

Gastrointestinal1 trial

Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients

Terminated·UUniversity of Pennsylvania·Phase 4·NCT00522548·37 enrolled

Medication1 trial

Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University··NCT00203281

Genetic Disorder1 trial

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00008307·52 enrolled

Tics1 trial

Pharmacokinetics of Mmf and Valganciclovir

Completed·UUniversity of Michigan·Phase 4·NCT00189150·16 enrolled

Mesenchymal Stem Cells1 trial

Cord Blood Expansion on Mesenchymal Stem Cells

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00498316·98 enrolled

Left Ventricular Hypertrophy1 trial

Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants

Completed·EEdoardo Melilli·Phase 4·NCT03415750·20 enrolled

Pilot Study1 trial

Pilot Study of Mycophenolate Mofetil in Congenital Uropathies

Completed·NNorthwell Health·Phase 1·NCT00193635·12 enrolled

Completed· Teva logo

Teva·Phase 1·NCT00910663·60 enrolled

Acute Leukemia1 trial

Total Marrow Irradiation for Refractory Acute Leukemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00686556·12 enrolled

Juvenile Myelomonocytic Leukemia1 trial

Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT01824693·30 enrolled

GvHD1 trial

In-Vivo Activated T-Cell Depletion to Prevent GVHD

Terminated·IIndiana University·N/A·NCT00594308·10 enrolled

Cardiac Transplant1 trial

The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients

Enrolling by invitation·—·Phase 2·NCT03292861·60 enrolled

Primary Biliary Cholangitis1 trial

Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy

Unknown status·WWest China Hospital·Phase 4·NCT04376528·89 enrolled

Melanoma1 trial

Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00006233

Gut Microbiome1 trial

Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects

Active, not recruiting·OOslo University Hospital·Phase 4·NCT04207177·100 enrolled

HIV infection1 trial

A Study of DAPD Alone Versus DAPD Plus MMF for Treatment of HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00038272·56 enrolled

Arthritis1 trial

Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis

Completed·OOklahoma Medical Research Foundation·Phase 1/2·NCT00594932·27 enrolled

Tic Disorder1 trial

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00176865·19 enrolled

Severe Aplastic Anemia1 trial

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT06412497·60 enrolled

Scleroderma1 trial

Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement

Completed·UUniversity of California, San Francisco·N/A·NCT00333437·7 enrolled

Cardiomyopathy1 trial

Immunosuppressive Treatment in Chronic Virus-Negative Inflammatory Cardiomyopathy

Terminated·LLMU Klinikum·Phase 2/3·NCT05570409·9 enrolled

Fanconi Anemia1 trial

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00453388·6 enrolled

Membranous Nephropathy1 trial

Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy

Unknown status·GGuangdong Provincial People's Hospital·Phase 4·NCT03170323·128 enrolled

Hematological Diseases1 trial

Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases

Completed·WWake Forest University Health Sciences·Phase 2·NCT02248597·27 enrolled

Interaction1 trial

Identification of Drug-drug Interaction Between Tacrolimus and Mycophenolate Mofetil in Healthy Adults

Completed·SSeoul National University Hospital·Phase 1·NCT02743247·18 enrolled

Breast Cancer1 trial

Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00365287·148 enrolled

Hemoglobinopathies1 trial

HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity

Completed·NNorthwell Health·Phase 1/2·NCT02435901·29 enrolled

Tacrolimus1 trial

Comparison of Two Tacrolimus Based Immunosuppressive Regimens in Recipients Receiving Marginal Donor Kidneys

Completed· Astellas logo

Astellas·Phase 3·NCT00321113·142 enrolled

Induction Therapy1 trial

MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN

Unknown status·SSecond Xiangya Hospital of Central South University·Phase 4·NCT05495893·224 enrolled

Bone Marrow Failure1 trial

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04232085·27 enrolled

Autoimmune Hepatitis1 trial

Mycophenolate Mofetil Versus Azathioprine in Treatment Naive Autoimmune Hepatitis

Unknown status·RRadboud University Medical Center·Phase 4·NCT02900443·70 enrolled

Pulmonary Fibrosis1 trial

Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis

Completed·NNorthwestern University·Phase 2·NCT02370693·9 enrolled

AML1 trial

HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk

Completed·TThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences·Phase 3·NCT02461121·156 enrolled

Renal Allograft Recipients1 trial

Study Comparing Two Immunosuppressive Regimens in De Novo Renal Allograft Recipients

Completed· Pfizer logo

Pfizer·Phase 4·NCT00261820·160 enrolled

Transplant Recipient1 trial

Outcomes in Pediatric Heart Transplant Recipients Receiving Cellcept

Terminated·EEmory University·N/A·NCT00166153·30 enrolled

Myelodysplastic Syndromes1 trial

Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00008177·79 enrolled

Nephropathy1 trial

The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients

Completed·FFan Fan Hou·N/A·NCT01854814·238 enrolled

Immune Thrombocytopenia1 trial

Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia

Withdrawn·WWeill Medical College of Cornell University·Phase 3·NCT02649504

Renal Transplantation1 trial

Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)

Unknown status·UUniversity of Cincinnati·Phase 4·NCT04849533·120 enrolled

Hepatitis1 trial

Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis

Unknown status·IInge Marie Svane·Phase 2·NCT04810156·60 enrolled

Multiple Myeloma1 trial

Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00054353·16 enrolled

HIV1 trial

MMF for HIV Reservoir Reduction

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT03262441·5 enrolled

Interstitial Lung Disease1 trial

Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases

Completed·UUniversity Hospital, Tours·Phase 3·NCT02990286·122 enrolled

Chronic Graft Versus Host Disease1 trial

Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

Recruiting· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT06682169·182 enrolled

Total Body Irradiation1 trial

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Recruiting·FFred Hutchinson Cancer Center·Phase 1/2·NCT04083183·40 enrolled

Sickle Cell Disease1 trial

Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease

Terminated·WWashington University School of Medicine·Phase 1·NCT02678143·1 enrolled

Pediatric Heart Transplantation1 trial

Alloantibodies in Pediatric Heart Transplantation

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)··NCT01005316·290 enrolled

Bone Marrow Transplant1 trial

Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer

Active, not recruiting·—·Phase 2·NCT00534430·30 enrolled

Tocilizumab1 trial

A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

Unknown status·YYi Luo·Phase 2·NCT04688021·46 enrolled

Transplantation1 trial

Trial Of Double Umbilical Cord Blood Transplantation

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00763490·20 enrolled

Unspecified1 trial

Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS

Completed·KKlemens Budde·Phase 4·NCT01801280·20 enrolled

Regulatory

FDA Approval Timeline[5]

May 3, 1995

CELLCEPT

NDA NDA050722

May 3, 1995

CELLCEPT

NDA NDA050722

Jun 19, 1997

CELLCEPT

NDA NDA050723

Jun 19, 1997

CELLCEPT

NDA NDA050723

Feb 11, 1998

CELLCEPT

NDA NDA050722

Apr 13, 1998

CELLCEPT

NDA NDA050722

Aug 12, 1998

CELLCEPT

NDA NDA050758

Aug 12, 1998

CELLCEPT

NDA NDA050758

Oct 1, 1998

CELLCEPT

NDA NDA050759

Jun 11, 1999

CELLCEPT

NDA NDA050759

Apr 20, 2000

CELLCEPT

NDA NDA050759

May 15, 2000

CELLCEPT

NDA NDA050722

Jun 16, 2000

CELLCEPT

NDA NDA050759

Jun 16, 2000

CELLCEPT

NDA NDA050758

Jun 16, 2000

CELLCEPT

NDA NDA050723

Jul 27, 2000

CELLCEPT

NDA NDA050722

Jul 27, 2000

CELLCEPT

NDA NDA050759

Jul 27, 2000

CELLCEPT

NDA NDA050758

Jul 27, 2000

CELLCEPT

NDA NDA050723

Jul 28, 2000

CELLCEPT

NDA NDA050758

Jul 28, 2000

CELLCEPT

NDA NDA050723

Jul 28, 2000

CELLCEPT

NDA NDA050722

Jul 28, 2000

CELLCEPT

NDA NDA050759

Dec 20, 2000

CELLCEPT

NDA NDA050759

Dec 20, 2000

CELLCEPT

NDA NDA050723

Dec 20, 2000

CELLCEPT

NDA NDA050722

Feb 1, 2001

CELLCEPT

NDA NDA050759

Oct 3, 2001

CELLCEPT

NDA NDA050759

Nov 14, 2001

CELLCEPT

NDA NDA050722

Nov 21, 2001

CELLCEPT

NDA NDA050759

Feb 27, 2002

CELLCEPT

NDA NDA050758

May 31, 2002

CELLCEPT

NDA NDA050722

Dec 17, 2002

CELLCEPT

NDA NDA050723

Dec 17, 2002

CELLCEPT

NDA NDA050758

Dec 17, 2002

CELLCEPT

NDA NDA050759

Feb 28, 2003

CELLCEPT

NDA NDA050723

Feb 28, 2003

CELLCEPT

NDA NDA050758

Feb 28, 2003

CELLCEPT

NDA NDA050759

Feb 28, 2003

CELLCEPT

NDA NDA050722

Apr 12, 2005

CELLCEPT

NDA NDA050758

Oct 17, 2005

CELLCEPT

NDA NDA050759

Oct 17, 2005

CELLCEPT

NDA NDA050758

Oct 17, 2005

CELLCEPT

NDA NDA050722

Oct 17, 2005

CELLCEPT

NDA NDA050723

Sep 21, 2007

CELLCEPT

NDA NDA050723

Sep 21, 2007

CELLCEPT

NDA NDA050758

Sep 21, 2007

CELLCEPT

NDA NDA050722

Sep 21, 2007

CELLCEPT

NDA NDA050759

Dec 20, 2007

CELLCEPT

NDA NDA050758

Dec 20, 2007

CELLCEPT

NDA NDA050759

Dec 20, 2007

CELLCEPT

NDA NDA050723

Dec 20, 2007

CELLCEPT

NDA NDA050722

May 9, 2008

CELLCEPT

NDA NDA050759

May 9, 2008

CELLCEPT

NDA NDA050722

May 9, 2008

CELLCEPT

NDA NDA050723

May 9, 2008

CELLCEPT

NDA NDA050758

Dec 15, 2008

CELLCEPT

NDA NDA050758

Dec 15, 2008

CELLCEPT

NDA NDA050723

Dec 15, 2008

CELLCEPT

NDA NDA050759

Dec 15, 2008

CELLCEPT

NDA NDA050722

Feb 27, 2009

CELLCEPT

NDA NDA050722

Feb 27, 2009

CELLCEPT

NDA NDA050723

Feb 27, 2009

CELLCEPT

NDA NDA050758

Feb 27, 2009

CELLCEPT

NDA NDA050759

Jun 18, 2009

CELLCEPT

NDA NDA050759

Jun 18, 2009

CELLCEPT

NDA NDA050758

Jun 18, 2009

CELLCEPT

NDA NDA050723

Jun 18, 2009

CELLCEPT

NDA NDA050722

Jul 22, 2009

CELLCEPT

NDA NDA050723

Oct 8, 2009

CELLCEPT

NDA NDA050759

Oct 8, 2009

CELLCEPT

NDA NDA050722

Oct 8, 2009

CELLCEPT

NDA NDA050723

Oct 8, 2009

CELLCEPT

NDA NDA050758

Jun 8, 2012

CELLCEPT

NDA NDA050759

Jun 8, 2012

CELLCEPT

NDA NDA050722

Jun 8, 2012

CELLCEPT

NDA NDA050723

Jun 8, 2012

CELLCEPT

NDA NDA050758

Jun 22, 2012

CELLCEPT

NDA NDA050758

Jun 22, 2012

CELLCEPT

NDA NDA050759

Jun 22, 2012

CELLCEPT

NDA NDA050722

Jun 22, 2012

CELLCEPT

NDA NDA050723

Sep 25, 2012

CELLCEPT

NDA NDA050758

Sep 25, 2012

CELLCEPT

NDA NDA050759

Sep 25, 2012

CELLCEPT

NDA NDA050722

Sep 25, 2012

CELLCEPT

NDA NDA050723

Feb 14, 2013

CELLCEPT

NDA NDA050723

Feb 14, 2013

CELLCEPT

NDA NDA050758

Feb 14, 2013

CELLCEPT

NDA NDA050759

Feb 14, 2013

CELLCEPT

NDA NDA050722

Jul 24, 2013

CELLCEPT

NDA NDA050759

Sep 27, 2013

CELLCEPT

NDA NDA050722

Sep 27, 2013

CELLCEPT

NDA NDA050722

Sep 27, 2013

CELLCEPT

NDA NDA050723

Sep 27, 2013

CELLCEPT

NDA NDA050723

Sep 27, 2013

CELLCEPT

NDA NDA050758

Sep 27, 2013

CELLCEPT

NDA NDA050758

Sep 27, 2013

CELLCEPT

NDA NDA050759

Sep 27, 2013

CELLCEPT

NDA NDA050759

Jan 23, 2014

CELLCEPT

NDA NDA050722

Jan 23, 2014

CELLCEPT

NDA NDA050723

Jul 9, 2015

CELLCEPT

NDA NDA050758

Jul 9, 2015

CELLCEPT

NDA NDA050723

Jul 9, 2015

CELLCEPT

NDA NDA050759

Jul 9, 2015

CELLCEPT

NDA NDA050722

Jul 16, 2015

CELLCEPT

NDA NDA050759

Nov 13, 2015

CELLCEPT

NDA NDA050758

Nov 13, 2015

CELLCEPT

NDA NDA050723

Nov 13, 2015

CELLCEPT

NDA NDA050722

Nov 13, 2015

CELLCEPT

NDA NDA050759

May 26, 2016

CELLCEPT

NDA NDA050758

Oct 27, 2016

CELLCEPT

NDA NDA050723

Dec 18, 2017

CELLCEPT

NDA NDA050759

Dec 18, 2017

CELLCEPT

NDA NDA050723

Dec 18, 2017

CELLCEPT

NDA NDA050722

Dec 18, 2017

CELLCEPT

NDA NDA050758

Aug 23, 2018

CELLCEPT

NDA NDA050723

Aug 23, 2018

CELLCEPT

NDA NDA050722

Aug 23, 2018

CELLCEPT

NDA NDA050759

Aug 23, 2018

CELLCEPT

NDA NDA050758

Feb 27, 2019

CELLCEPT

NDA NDA050758

Feb 27, 2019

CELLCEPT

NDA NDA050723

Feb 27, 2019

CELLCEPT

NDA NDA050722

Feb 27, 2019

CELLCEPT

NDA NDA050759

Dec 13, 2019

CELLCEPT

NDA NDA050723

Dec 13, 2019

CELLCEPT

NDA NDA050759

Dec 13, 2019

CELLCEPT

NDA NDA050758

Dec 13, 2019

CELLCEPT

NDA NDA050722

Jan 15, 2021

CELLCEPT

NDA NDA050722

Jan 15, 2021

CELLCEPT

NDA NDA050759

Jan 15, 2021

CELLCEPT

NDA NDA050758

Jan 15, 2021

CELLCEPT

NDA NDA050723

Apr 21, 2021

CELLCEPT

NDA NDA050722

Apr 21, 2021

CELLCEPT

NDA NDA050723

Apr 21, 2021

CELLCEPT

NDA NDA050758

Apr 21, 2021

CELLCEPT

NDA NDA050759

Aug 11, 2021

CELLCEPT

NDA NDA050723

Aug 11, 2021

CELLCEPT

NDA NDA050758

Aug 11, 2021

CELLCEPT

NDA NDA050759

Aug 11, 2021

CELLCEPT

NDA NDA050722

Oct 22, 2021

CELLCEPT

NDA NDA050722

Oct 22, 2021

CELLCEPT

NDA NDA050759

Oct 22, 2021

CELLCEPT

NDA NDA050723

Oct 22, 2021

CELLCEPT

NDA NDA050722

Oct 22, 2021

CELLCEPT

NDA NDA050759

Oct 22, 2021

CELLCEPT

NDA NDA050758

Oct 22, 2021

CELLCEPT

NDA NDA050758

Oct 22, 2021

CELLCEPT

NDA NDA050723

Jun 6, 2022

CELLCEPT

NDA NDA050759

Jun 6, 2022

CELLCEPT

NDA NDA050722

Jun 6, 2022

CELLCEPT

NDA NDA050722

Jun 6, 2022

CELLCEPT

NDA NDA050723

Jun 6, 2022

CELLCEPT

NDA NDA050723

Jun 6, 2022

CELLCEPT

NDA NDA050758

Jun 6, 2022

CELLCEPT

NDA NDA050758

Jun 6, 2022

CELLCEPT

NDA NDA050759

Aug 10, 2022

CELLCEPT

NDA NDA050723

Aug 10, 2022

CELLCEPT

NDA NDA050758

Aug 10, 2022

CELLCEPT

NDA NDA050722

Aug 10, 2022

CELLCEPT

NDA NDA050759

May 1, 2024

MYHIBBIN

NDA NDA216482

Aug 13, 2024

CELLCEPT

NDA NDA050722

Aug 13, 2024

CELLCEPT

NDA NDA050759

Aug 13, 2024

CELLCEPT

NDA NDA050758

Aug 13, 2024

CELLCEPT

NDA NDA050723

Jun 27, 2025

CELLCEPT

NDA NDA050723

Jun 27, 2025

CELLCEPT

NDA NDA050759

Jun 27, 2025

CELLCEPT

NDA NDA050722

Jun 27, 2025

CELLCEPT

NDA NDA050758

Jul 29, 2026

CELLCEPT

NDA NDA050758

Jul 29, 2026

CELLCEPT

NDA NDA050722

Jul 29, 2026

CELLCEPT

NDA NDA050723

Jul 29, 2026

CELLCEPT

NDA NDA050759

Jul 29, 2026

CELLCEPT

NDA NDA050758

Jul 29, 2026

CELLCEPT

NDA NDA050723

Jul 29, 2026

CELLCEPT

NDA NDA050722

Jul 29, 2026

CELLCEPT

NDA NDA050759

Sources

References

[1]
ClinicalTrials.gov — 622 trial records for Mycophenolate Mofetil. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — CellCept drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Mycophenolate Mofetil compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Mycophenolate Mofetil. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA050758). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for CellCept. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Inosine-5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Roche

Patent Landscape[6]

Patent Cliff

Aug 16, 2039

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12194143Aug 16, 2039

12097285Aug 16, 2039

12226526Aug 16, 2039

11931455Aug 16, 2039

12097284Aug 16, 2039

CellCept

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Q4 2028

Trials by Indication[1]

Kidney Transplant18 trials

Stem Cell Transplant15 trials

Hematologic Malignancies9 trials

Lupus Nephritis8 trials

Kidney Cancer6 trials

Acute Myeloid Leukemia5 trials

Acute Graft Versus Host Disease5 trials

Liver Transplant5 trials

Acute Lymphoblastic Leukemia4 trials

Lymphoma4 trials

Treatment4 trials

Renal Transplant Recipients4 trials

Bone Marrow Transplantation4 trials

Systemic Lupus Erythematosus4 trials

Efficacy and Safety4 trials

Nephrotic Syndrome4 trials

Chronic Myelogenous Leukemia3 trials

Graft Versus Host Disease3 trials

Chronic Lymphocytic Leukemia2 trials

Kidney2 trials

Stem Cell Transplantation2 trials

Renal Transplant2 trials

Uveitis2 trials

Aplastic Anemia2 trials

Immunosuppression2 trials

Hematologic Disease2 trials

Allogeneic Hematopoietic Stem Cell Transplantation2 trials

Pemphigus Vulgaris2 trials

Safety and Efficacy2 trials

Vasculitis2 trials

Hematopoietic Stem Cell Transplantation2 trials

Systemic Sclerosis2 trials

Histiocytosis1 trial

Pancreatic Cancer1 trial

Myeloproliferative Disorder1 trial

Fasting Conditions1 trial

Natural Killer Cell1 trial

Allogeneic Stem Cell Transplantation1 trial

Hematological Malignancies1 trial

Trial1 trial

Monoclonal1 trial

Juvenile Neuronal Ceroid Lipofuscinosis1 trial

Gastrointestinal1 trial

Medication1 trial

Genetic Disorder1 trial

Tics1 trial

Mesenchymal Stem Cells1 trial

Left Ventricular Hypertrophy1 trial

Pilot Study1 trial

Thalassemia1 trial

Hematologic Cancer1 trial

Fed1 trial

Acute Leukemia1 trial

Juvenile Myelomonocytic Leukemia1 trial

GvHD1 trial

Cardiac Transplant1 trial

Primary Biliary Cholangitis1 trial

Melanoma1 trial

Gut Microbiome1 trial

HIV infection1 trial

Arthritis1 trial

Tic Disorder1 trial

Severe Aplastic Anemia1 trial

Scleroderma1 trial

Cardiomyopathy1 trial

Fanconi Anemia1 trial

Membranous Nephropathy1 trial

Hematological Diseases1 trial

Interaction1 trial

Breast Cancer1 trial

Hemoglobinopathies1 trial

Tacrolimus1 trial